Chemistry:Dusigitumab

From HandWiki
Short description: Chemical compound
Dusigitumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetIGF2
Clinical data
ATC code
  • none
Identifiers
CAS Number
IUPHAR/BPS
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6372H9824N1700O2016S54
Molar mass144233.81 g·mol−1

Dusigitumab is a human monoclonal antibody designed for the treatment of cancer. It binds to IGF2.[1][2] It was developed by MedImmune, which was acquired by AstraZeneca, using Xenomouse technology licensed from Abgenix.[3] Its development has been discontinued.[2]

References

  1. "Dusigitumab". Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association. http://www.ama-assn.org/resources/doc/usan/dusigitumab.pdf. 
  2. 2.0 2.1 "Therapeutic Targeting of the IGF Axis". Cells 8 (8): 895. August 2019. doi:10.3390/cells8080895. PMID 31416218. 
  3. "Dusigitumab - MedImmune". AdisInsight. Springer Nature Switzerland AG. http://adisinsight.springer.com/drugs/800030209.